Almonertinib
- Generic Name
- Almonertinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H35N7O2
- CAS Number
- 1899921-05-1
- Unique Ingredient Identifier
- T4RS462G19
- Background
Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations. It is being investigated against advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).
- Indication
1.用于既往经表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗时或治疗后出现疾病进展，并且经检测确认存在EGFR T790M 突变阳性的局部晚期或转移性非小细胞肺癌成人患者的治疗。
2.用于表皮生长因子受体（EGFR）敏感突变阳性局部晚期或转移性非小细胞肺癌（NSCLC）患者一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients
- Conditions
- Interventions
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 429
- Registration Number
- NCT03849768
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC
- First Posted Date
- 2016-12-02
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 364
- Registration Number
- NCT02981108
- Locations
- 🇺🇸
Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸University of Texas Medical Branch at Galveston, Galveston, Texas, United States
🇺🇸Beverly Hills Cancer Center, Beverly Hills, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.